RSV Vaccines for the World

14-16 October 2013, Tiara Park Atlantico Hotel, Porto, Portugal

  • Increase font size
  • Default font size
  • Decrease font size

Poster Session

Poster 101
‘Recombinant RSV strains with enhanced fusion activity exhibit relatively high viral load and pathogenicity in BALB/c mice’
Martin L. Moore et al. (Emory University, Atlanta, Georgia, USA)

Poster 102
‘A role for TLR-environment interactions effected through T helper type 2 polarization in severe RSV bronchiolitis’
Fernando P. Polack et al. (Vanderbilt University, Nashville, Tennessee, USA)

Poster 103
‘Targeting passive prophylaxis: Gender and breastfeeding determine susceptibility for severe respiratory syncytial virus (RSV) infection and protective efficacy of palivizumab in very low birth weight infants in a developing country’
Fernando P. Polack et al. (Vanderbilt University, Nashville, Tennessee, USA)

Poster 104
‘Targeting vaccines against respiratory pathogens: Deaths in hospitalized infants in a developing country’
Fernando P. Polack et al. (Vanderbilt University, Nashville, Tennessee, USA)

Poster 105
‘Targeting the RSV fusion receptor reduces viral replication and airway inflammation in mice’
Peter Mastrangelo et al. (University of Toronto, Toronto, Ontario, Canada)

Poster 106
‘The RSV fusion protein formulated with a novel combination adjuvant induces protective immunity in lambs with maternal antibodies’
Ravendra Garg et al. (VIDO, University of Saskatchewan, Saskatoon, Canada)

Poster 107
‘Nasal immunization of cotton rats with recombinant RSV lacking glycoprotein G induces long term protection against RSV challenge infection’
Jolande Boes et al. (Intravacc, Bilthoven, The Netherlands)

Poster 108
‘Vaccine concept based on a respiratory syncytial virus with a genomic deficiency complemented in trans’
Otto de Boer (Intravacc, Bilthoven, The Netherlands)

Poster 109
‘Automated quantitative image analysis of goblet cell hyperplasia in a mouse model of RSV infection’
Simone P. Zehntner et al. (Biospective Inc., Montreal, Quebec, Canada)

Poster 110
‘Molecular and structural characterization of RSV F antigen designed to adopt pre-fusion conformation and comparison with F antigen in post-fusion conformation’
Normand Blais et al. (GlaxoSmithKline Vaccines, Laval, Quebec, Canada)

Poster 111
‘Cellular and humoral immune responses to RSV exposure in health care workers’
Christopher Green et al. (University of Oxford, Oxford, UK)

Poster 112
‘Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice’
Lia M. Haynes et al. (CDC, Atlanta, Georgia, USA)

Poster 113
‘Immunogenicity, efficacy and safety of a respiratory syncytial virus recombinant F protein vaccine in cotton rats’
Ann-Muriel Steff et al. (GlaxoSmithKline Vaccines, Laval, Quebec, Canada)

Poster 114
‘Proof of concept of the efficacy of a maternal RSV, recombinant F protein, vaccine for protection of offspring in the guinea pig model’
Ann-Muriel Steff et al. (GlaxoSmithKline Vaccines, Laval, Quebec, Canada)

Poster 115
‘Differential RSV seasonal patterns in Florida, Puerto Rico and other US regions’
Marika Iwane et al. (CDC, Atlanta, Georgia, USA)

Poster 116
‘Investigation of respiratory syncytial virus-associated deaths among children in four US states, 2004-2007’
Mila M. Prill et al. (CDC, Atlanta, Georgia, USA)

Poster 117
‘RSV-vaccine candidates based on a modified vaccinia virus Ankara (MVA) platform technology for the prevention of diseases caused by respiratory syncytial virus’
Kathrin Kindsmueller and Sonia Leyrer (Emergent BioSolutions Inc., Rockville, Maryland, USA)

Poster 118
‘Characterization of recombinant adeno-associated virus vectors expressing RSVF neutralizing antibodies’
Rebecca J. Loomis and Philip R. Johnson (Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA)

Poster 119
‘Assessing promising practices and barriers for improving influenza vaccine coverage among employees in Pennsylvania health Care Facilities’
Sara Ferrick and O. Simwale (The Pennsylvania State University, Harrisburg, Pennsylvania, USA)

Poster 120
‘Safety, reactogenicity and immunogenicity of a single intramuscular dose of two formulations of a candidate RSV vaccine in healthy adults aged 18-51 years: a phase I, single-blind, randomized comparative study’
Jean-Francois X. Toussaint et al. (GlaxoSmithKline Vaccines, Rixensart, Belgium)

Poster 121
‘Immunogenicity, reactogenicity and safety of three formulations of a candidate RSV vaccine, each administered as a single intramuscular dose in healthy adults aged >65 years: a double-blind randomized study’
Edward Walsh et al. (University of Rochester, Rochester, New York, USA)

Poster 122
‘A rationally designed woodchuck hepadnavirus VLP displaying RSV palivizumab epitope elicits RSV neutralizing antibody and protects mice from challenge’
David C. Whitacre et al. (VLP Biotech Inc., San Diego, California, USA)

Poster 123
‘Co-immunization with VLP and DNA vaccines confers protection against RSV without pulmonary inflammatory disease’
Sang-Moo Kang et al. (Georgia State University, Atlanta, Georgia, USA)

Poster 124
‘Differential outcomes of maternal antibodies in protection and disease’
Sang-Moo Kang et al. (Georgia State University, Atlanta, Georgia, USA)

Poster 125
‘The burden of respiratory syncytial virus (RSV) infection in children in the United Kingdom’
Sylvia Taylor et al. (GlaxoSmithKline Vaccines, Wavre, Belgium)

Poster 126
‘The burden of respiratory syncytial virus (RSV) infection in adults and the elderly in the United Kingdom’
Douglas Fleming et al. (Independent Consultant, Birmingham, UK)

Poster 127
‘Molecular epidemiology of respiratory syncytial virus (RSV) in Fukushima, Japan, 2007-2012 and evaluation of clinical RSV strains using mouse infection model’
Koichi Hashimoto et al. (Fukushima Medical University, Fukushima, Japan)

Poster 128
‘Burden of human respiratory syncytial virus (RSV) infection’
Ida Kolte et al. (Crucell Holland BV, Leiden, The Netherlands)

Poster 129
‘Protection of cotton rats against human respiratory syncytial virus infection by mRNA-based vaccination without disease enhancement’
M. Fotin-Mleczek et al. (CureVac GmbH, Tubingen, Germany)

Poster 130
‘A study of inactivated trivalent influenza vaccine among children in rural India 2009-2010: a possible platform for future RSV vaccine trials’
Wayne Sullender et al. (University of Colorado Denver, Denver, Colorado, USA)

Poster 131
‘Impaired learning resulting from respiratory syncytial virus infection’
Sebastian A. Riquelme et al. (Potificia Universidad Catolica de Chile, Santiago, Chile)

Poster 132
‘Contribution of FcΓ receptors to respiratory syncytial virus pathogens and the impairment of T cell activation by dendritic cells’
Roberto S. Gomez et al. (Potificia Universidad Catolica de Chile, Santiago, Chile)

Poster 133
‘Immunization with a recombinant BCG strain confers protective Th1 immunity against the human metapneumovirus’
Susan M. Bueno et al. (Potificia Universidad Catolica de Chile, Santiago, Chile)

Poster 134
‘The source of respiratory syncytial virus infection in infants: A household cohort study in rural kenya’
Patrick K. Munywoki et al. (KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya)

 

RSVVW 2013 Sponsors

  • Mymetics
  • Aldevron
  • Crucell
  • Novavax
  • PATH
  • NatureGeneTherapy.com
  • Novartis Vaccines
  • Sanofi Pasteur
  • Inovio Pharmaceuticals
  • VLP Biotech
  • ADMA Biologics
  • Ablynx
  • Mucosis
  • Immunovaccine
  • NanoBio
  • Aldevron
  • Okairos
  • Pevion Vaccines
  • Retroscreen Virology

RSVVW 2013 Downloads

RSVVW 2013 Leaflet

RSVVW 2013 Mailing List

Name
E-mail Address
What is 1+4-2?